Cholic acid
( DrugBank: Cholic Acid / KEGG DRUG: Cholic acid )
4 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
20 | Adrenoleukodystrophy | 2 |
234 | Peroxisomal disease (except Adrenoleukodystrophy) | 3 |
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
265 | Lipodystrophy | 1 |
310 | Congenital anomalies syndrome | 1 |
20. Adrenoleukodystrophy
Clinical trials : 68 / Drugs : 74 - (DrugBank : 32) / Drug target genes : 25 - Drug target pathways : 131
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
234. Peroxisomal disease (except Adrenoleukodystrophy)
Clinical trials : 115 / Drugs : 59 - (DrugBank : 20) / Drug target genes : 15 - Drug target pathways : 50
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
265. Lipodystrophy
Clinical trials : 127 / Drugs : 137 - (DrugBank : 58) / Drug target genes : 28 - Drug target pathways : 99
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
310. Congenital anomalies syndrome
Clinical trials : 12 / Drugs : 16 - (DrugBank : 9) / Drug target genes : 3 - Drug target pathways : 8
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|